The Department of Defense is offering the NFRP Clinical Trial Award to support the rapid implementation of clinical trials aimed at impacting the treatment or management of Neurofibromatosis (NF). Projects can include evaluating new products, pharmacologic agents, devices, clinical guidance, or emerging technologies. From small proof-of-concept trials to large-scale efficacy evaluations, this grant supports a wide range of clinical trial initiatives. The closing date for application submission is July 22, 2021.
Opportunity ID: 333214
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-21-NFRP-CTA |
| Funding Opportunity Title: | DOD Neurofibromatosis, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 30, 2021 |
| Last Updated Date: | Apr 30, 2021 |
| Original Closing Date for Applications: | Jul 22, 2021 |
| Current Closing Date for Applications: | Jul 22, 2021 |
| Archive Date: | Aug 21, 2021 |
| Estimated Total Program Funding: | $20,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 333214 Full Announcement-FY21 NFRP CTA -> NFRP FY21 CTA PA_GG.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00266834 | Apr 30, 2021 | Jul 22, 2021 | View |
Package 1
Mandatory forms
333214 RR_SF424_3_0-3.0.pdf
333214 AttachmentForm_1_2-1.2.pdf
333214 RR_PersonalData_1_2-1.2.pdf
333214 RR_KeyPersonExpanded_3_0-3.0.pdf
333214 RR_Budget_1_4-1.4.pdf
333214 PerformanceSite_3_0-3.0.pdf
Optional forms
333214 RR_SubawardBudget30_1_4-1.4.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
